The European Commission’s proposed Biotech Act, also known as Biotech Act I, is at the heart of a broader strategy to make the EU a more attractive destination for life sciences.
The Biotech Act (which comprises a Regulation and a Directive) is intended to support the development and commercialisation of health-focused biotechnology products by addressing longstanding barriers within the EU, including fragmented governance, underutilised manufacturing capacity, limited scale-up funding, regulatory complexity and delays in clinical trial approvals. If passed in its proposed form, the Biotech Act package would amend EU legislation spanning clinical trials, advanced therapy medicinal products, substances of human origin, veterinary medicinal products, general food law, human organs, and genetically modified organisms. It would also align with other proposed legislation (such as the proposed Critical Medicines Act, and revision of EU pharmaceutical legislation – the Pharma Package).
In addition to the proposed Biotech Act the following proposals are under development:
A Regulation aimed at simplifying the medical devices and in vitro diagnostic medical devices frameworks.
A Biotech Directive addressing genetically modified micro-organisms and human organ processing.
A further legislative package, Biotech Act II, which will complement the Biotech Act broadening the focus beyond health biotechnology to industrial biotechnology and biomanufacturing.
Biotech Act - key proposals
Strategic projects and biomanufacturing support
Frameworks for supporting projects recognised as “strategic” and “high-impact” would be introduced. These would include projects that create or expand production facilities, establish innovative and digitally enabled biomanufacturing sites, or integrate AI-driven manufacturing systems.
Qualifying projects would benefit from accelerated permit timelines, more efficient regulatory procedures and potentially greater access to financial support.
A European Health Biotechnology Steering Group would also be established, intended to facilitate communication between EU Member States and the Commission to ensure biotech projects are effectively recognised and implemented.
Access to funding and investment
The Regulation proposes two pilots to address the so-called “valley of death” funding problem faced by many earlier stage biotech start-ups: an EU Health Biotechnology Investment Pilot focused on mobilising funding for biotech R&D, and a Late Stage Capital Booster Pilot aimed at strengthening access to later-stage capital for EU biotech companies.
The Regulation also encourages state aid by designating biotech as a strategic technology and encouraging EU member states to use state aid instruments to support the sector.
Clinical trials
A central pillar of the proposal is reform of the EU clinical trials regime under the EU Clinical Trials Regulation.
Approval timelines for multinational clinical trials would be shortened from 106 days to 75 days, or as little as 47 days where no additional relevant information is required. Timelines for substantial modifications would similarly be compressed, and the additional 50-day assessment period for advanced therapy medicinal products (medicines based on advanced techniques involving genes, tissues or cells) would be removed.
The role of the lead EU country “reporting Member State” would be strengthened, with its assessment forming the basis for other countries’ decisions. Ethical review would be integrated into the main scientific assessment of clinical trial dossiers, and reliance mechanisms would reduce duplication across jurisdictions.
Additional tools would be introduced, including:
A simplified, minimal-intervention trial category for lower risk studies involving medicines which are already authorised.
An investigational product core dossier allowing clinical trial sponsors to maintain a single product file reused across trials.
Accelerated pathways for clinical trials during public health emergencies.
Explicit recognition of electronic informed consent for clinical trial participants.
Together, these reforms are intended to improve the EU’s attractiveness as a location for clinical research, in the face of increased international competition. They share similarities with recent UK reforms.
Regulatory sandboxes
A range of new regulatory sandboxes are envisaged, allowing developers to test innovative products under supervisory oversight and more flexible regulatory conditions before full market entry.
Data protection
Currently EU countries take different approaches to the correct legal basis under data protection law for processing clinical trial-related personal data. A harmonised approach is proposed, with no additional national requirements, aiming to reduce fragmentation and compliance costs for trial sponsors.
European data protection bodies have expressed support, while asking for further clarification, particularly in relation to data controller roles, secondary use of clinical trial data for other scientific research, and pseudonymisation of personal data where this is possible.
Artificial Intelligence
As AI becomes more widely used in clinical research, sponsors would be required to evaluate benefits and risks to patient safety and data robustness of any AI models or systems used in the context of clinical trials. They would need to include a description of how AI tools are used in the trial protocol.
European data protection bodies have sought to clarify that these new requirements would apply in addition to those under the EU AI Act. In addition, Europe’s medicines regulator, the EMA, has stated it will issue guidance on use of AI in the life cycle of medicines.
Intellectual property
A 12-month extension to Supplementary Protection Certificates (SPCs) for biological medicines and advanced therapy medicinal products meeting specified innovation, EU clinical-trial and manufacturing criteria would be introduced. An SPC can extend protection for an authorised medicine for up to 5 years where patent life has been eaten up through regulatory processes. However, the current scope of this proposal has been observed as too narrow. The pharmaceutical industry’s trade association in Europe, the EFPIA, has welcomed the proposed introduction, however research commissioned by it suggests its effectiveness would be maximised by focusing on broad scope and flexible eligibility criteria.
Biosecurity and biodefence
Harmonised rules intended to prevent biotech misuse would be introduced, including screening and reporting obligations for high-risk products and benchtop nucleic acid synthesis equipment and enforcement mechanisms to ensure compliance. Emerging risks would then be monitored by an Advisory Group.
Biosimilars
The proposal includes measures to promote EU competitiveness in biosimilars R&D and manufacturing including by developing EMA guidelines covering biosimilars, supporting projects focused on development, manufacturing and marketing authorisation and promoting international cooperation.
GMO and food sector reforms
The proposal would amend the EU's General Food Law (Regulation (EC) No 178/2002) to ease the path for genetically modified (GM) agri-food products. Applicants seeking authorisation or renewal of GM products would be able to request pre-submission advice from the European Food Safety Authority (EFSA) on study design and testing strategies. Where applicants have not notified supporting studies to EFSA in advance, resubmitted applications would be assessed more quickly, within three months of notification rather than six.
A further, food-specific regulatory sandbox is proposed, allowing companies to test innovative food products, including GM foods but excluding novel foods, at the pre-market stage in a controlled environment for a limited period. Together, these measures are intended to reduce delay and uncertainty in the GM authorisation pathway, which has long been a barrier to bringing new agri-food biotechnology to the EU market.
Where does the proposal stand?
The proposed Biotech Act is progressing through the EU’s legislative procedure, with a first reading in the European Parliament expected in December 2026.
The proposal is likely to be further refined before adoption with detailed scrutiny and negotiations. Once implemented, the package promises to address some of the headwinds which EU biotech currently faces, as well as streamlining activity for international businesses seeking to carry out clinical research in the EU or establish manufacturing facilities, for example.
We will report on these proposals as they develop.
Our content explained
Every piece of content we create is correct on the date it’s published but please don’t rely on it as legal advice. If you’d like to speak to us about your own legal requirements, please contact one of our expert lawyers.